Chr. Hansen has said that it is on track after a strong second quarter, and is maintaining its outlook for the year.
“Following a strong Q2 with 10% organic growth and solid margin development we remain on track to deliver on our outlook for the full year, expecting organic revenue growth of 7-9% and an EBIT margin before special items above 26%,” says CEO Cees de Jong.
“We have continued to implement our Nature’s No. 1 strategy with initiatives to support the future growth and profitability of Chr. Hansen. I am especially pleased with the good performance of both the Cultures & Enzymes Division and the EMEA region in general as well as to see the first sales of cultures for crop protection.”
Revenues for the first half year were €353 million, unchanged from first half 2012/13, with organic growth of 6%. EBIT before special items and impairments was €88 million and EBIT margin before special items and impairments 25.0%, both unchanged from last year
In the second quarter, revenue was €182 million, up 4% on last year, with organic growth of 10%. EBIT margin before special items and impairments was 24.8%, up from 23.3% last year
